Heart drug mavacamten shows promise in Real-World HCM patients
NCT ID NCT07529938
First seen Apr 17, 2026 · Last updated May 23, 2026 · Updated 7 times
Summary
This study tested the drug mavacamten in 222 adults with a type of heart disease called obstructive hypertrophic cardiomyopathy (oHCM), which makes the heart muscle thick and blocks blood flow. Researchers compared patients who got mavacamten to those on standard treatment, measuring changes in heart pressure and symptoms after 30 weeks. The goal was to see if mavacamten safely improves heart function in everyday medical practice.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERTROPHIC CARDIOMYOPATHY (HCM) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Fuwai Central China Cardiovascular Hospital
Zhengzhou, Henan, 450000, China
Conditions
Explore the condition pages connected to this study.